-
Kuros Biosciences to showcase new MagnetOs products at NASS 2021 Annual Meeting
. New products expand perioperative solutions for surgeons Data to be presented on new formulation of MagnetOs that includes a collagen carrier Kuros Biosciences (“Kuros” or the “Company”), a leader in next generation bone graft technologies, announced today that it will showcase new products in the MagnetOs range at the 36th Annual Meeting of the North American Spine Society (NASS), being held in Boston from September 29 to October 2, 2021. Joost de Bruijn, Chief Executive Officer of Kuros, said: "We are on a mission to ease the burden of spine-related pain through superior biologics for better spinal fusions. These new products demonstrate Kuros‘ commitment to that goal. Adding new…
-
Kuros Biosciences Reports Results for First Half 2021
. Financial Highlights CHF 29.4 million cash & cash equivalents, trade and other receivables as of June 30, 2021 Received CHF 5.5 million milestone payments from Checkmate Pharmaceuticals Acceleration of product sales to CHF 3.6 million, up from CHF 1.3 million in H1 2020 Net operating costs of CHF 8.6 million, increase led by higher marketing expenses Operational Highlights First patient treated in clinical trial of MagnetOs Putty posterolateral spine fusion Signed sales and distribution agreements across Europe Positive clinical outcomes from investigator-led clinical study of MagnetOs To receive $7 million up front and potentially $166.5 million in future revenues under royalty purchase agreement with XOMA related to license agreement…
-
Kuros to receive $7 million up front and potentially $166.5 million in future revenues under a royalty purchase agreement with XOMA related to Kuros’s license agreement with Checkmate Pharmaceuticals
Kuros Biosciences AG (“Kuros” or the “Company”), a leader in next generation bone graft technologies, announced today that it has entered into a royalty purchase agreement with XOMA Corporation (NASDAQ: XOMA) under which XOMA has purchased a proportion of the potential future pre-commercial milestone payments and all the potential royalties due under the existing license agreement between Kuros and Checkmate Pharmaceuticals related to one of Kuros’s assets outside of the bone graft field. Kuros will receive an initial payment of $7 million from XOMA. In addition, Kuros retains the potential to receive up to $24 million in pre-commercial milestones from Checkmate, and is eligible to receive up to $142.5 million…
-
Kuros Biosciences announces publication of data on MagnetOs in eCM Journal linking MOA to enhanced predictable bone regeneration
. First peer-reviewed article with demonstrated efficacy in preclinical and clinical studies Outlines ability of MagnetOs to deliver uniform, stable and reliable bone fusions Kuros Biosciences (SIX: KURN) today announced the publication of new data in eCM Journal, a peer-reviewed publication focusing on preclinical re-search in the musculoskeletal field, on the mechanism of action of its MagnetOs bone graft. The paper describes how immunomodulation by bone grafts with submicron topographical fea-tures translates to enhanced bone regeneration and successful spinal fusion. This is the first and only fully-translational peer-reviewed article for a bone graft material, describing evidence of its performance from benchtop to the clinic. Joost de Bruijn, Chief Executive Officer…
-
Kuros Biosciences to present at upcoming U.S. spine conferences
Kuros Biosciences (SIX: KURN), a leader in next generation bone graft technologies and a pioneer in the emerging field of osteoimmunology, today announced that high-profile surgeons will present on the STRUCTURE clinical trial with Fibrin-PTH and on preclinical and clinical data for MagnetOs bone graft at the upcoming 16th annual meeting of the Korean American Spine Society, and at the Spine Summit 2021. Company management will also attend several U.S. clinical conferences in June, July and August. MagnetOs bone graft is supported by a growing set of preclinical data demonstrating equiva-lence to the current gold standard, autograft, with over three years of clinical experience since its first use in the…
-
Kuros Biosciences’s commercial roll-out of MagnetOs bone graft exceeds expectations
MagnetOs U.S. Q1 sales accelerate, rising 117% over Q1 2020 European distribution network expansion ahead of schedule Key commercial events in Australia, UK Kuros Biosciences (SIX: KURN), a leader in next generation bone graft technologies, today pro-vided an update on its commercial activities, with sales of MagnetOs bone graft and progress in establishing distributor networks both exceeding management expectations. Direct sales of MagnetOs in the U.S. accelerated in Q1 2021, with an increase of 117% over the same quarter in 2020. In Europe, third-party distributor agreements have recently been signed in Spain, Italy, Norway, Sweden, Denmark, and France. These add to existing distribu-tor network agreements in Switzerland and the…
-
Kuros to receive $4 million milestone payment from Checkmate Pharmaceuticals
. • Milestone triggered by Checkmate’s initiation of potential registration trial of vidutolimod (CMP-001) in patients with anti-PD-1 refractory advanced melanoma • Kuros stands to receive up to $49 million additional milestones plus royalties on sales Kuros Biosciences (“Kuros”), a leader in next generation bone graft technologies, today announced it will receive a milestone payment of $4 million from Checkmate Pharmaceuticals, Inc. related to dosing of the first patient in a Phase 2 trial of vidutolimod (CMP-001) in combination with nivolumab for the treatment of patients with anti-PD-1 refractory advanced melanoma, under a license agreement between the companies. Checkmate recently initiated a Phase 2 trial evaluating vidutolimod in…
-
Kuros Biosciences strengthens its patent position on use of Fibrin-PTH in spinal fusion
Kuros Biosciences AG (SIX: KURN), a leader in next generation bone graft technologies, today announced that its subsidiary, Kuros Biosurgery AG, has been granted European patent EP 2686027, entitled ‘Pharmaceutical Formulation for Use in Spinal Fusion’. This patent claims certain matrix materials in combination with parathyroid hormone (PTH) or derivatives of PTH. This patent strengthens the intellectual property around Fibrin-PTH, Kuros’s drug-biologic combination product for bone generation. Fibrin-PTH (KUR-113) has recently entered a Phase 2 clinical study in spinal fusion and is recruiting patients at multiple sites in the U.S. Joost de Bruijn, Chief Executive Officer of Kuros, said: “Adding this patent to our broad intellectual property portfolio further reinforces…
-
Kuros Biosciences publishes invitation to the Annual General Meeting 2021
Kuros Biosciences (SIX: KURN), a leader in next generation bone graft technologies and a pioneer in the emerging field of osteoimmunology, today published the invitation and agenda for its Annual General Meeting, to be held on April 19, 2021, 11.00 a.m. The Annual General Meeting will be held under conditions of the Federal Council’s Ordinance 3 on Measures to Combat the Coronavirus (COVID-19) (COVID-19-Ordinance-3) as in force today. Due to current restrictions resulting from the COVID-19 pandemic, physical attendance to the meeting will not be possible and shareholders can cast their votes only by the independent proxy. Please consult the invitation for further information. Kuros Biosciences recently announced…
-
Kuros Biosciences reports results for the full year 2020
Financial highlights CHF 29.8 million cash & cash equivalents, trade and other receivables at December 31, 2020 Revenues increased by 58% to CHF 4.0 million Operational highlights Initiated Phase II clinical study of Fibrin-PTH in spine Commercial rollout in the U.S. and Europe on track Distribution agreements for The Netherlands, Austria, and Switzerland for MagnetOs Raised CHF 18.6 million to advance product pipeline and commercialization of MagnetOs Kuros Biosciences closed the year with outstanding results for 2020, accelerating sales by 58% and initiating the Phase II study for Fibrin PTH, confirming its successful transition into a fully-fledged orthobiologics company with scientific, clinical, and commercial excellence in bone regeneration. Kuros raised…
